# CGMP MANUFACTURE OF TWO HIV DNA VACCINES AND ONE HIV PROTEIN VACCINE COMPONENT

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2022 · $57,745

## Abstract

This request to Biopharmaceutical Development Program (BDP) at the Frederick National Laboratory for Cancer Research (FNLCR) for the cGMP manufacture of HIV-based DNA and protein vaccine components. These clinical products will be used to test the immunogenicity and safety of HIV vaccine candidates in a phase I clinical trial. These immunogens, never tested in humans, include novel HIV gp160 envelope immunogens engineered to minimize antibody interference in a vaccine platform that elicits long lasting monocytes memory responses to HIV. Specifically, we are requesting the cGMP production of:
1)	HIV clade A/E A244∆V1 gp160 DNA vaccine
2)	HIV clade B A244∆V1 Gag DNA vaccine
3)	HIV clade A/E A244 gp120 protein deleted in V1 and engineered to maintain V2 in an α-helix conformation (A244∆V1gp120).

## Key facts

- **NIH application ID:** 10655272
- **Project number:** 75N91019D00024-P00006-759102000027-1
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** TARA BUTLER
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $57,745
- **Award type:** —
- **Project period:** 2020-09-25 → 2024-09-24

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10655272

## Citation

> US National Institutes of Health, RePORTER application 10655272, CGMP MANUFACTURE OF TWO HIV DNA VACCINES AND ONE HIV PROTEIN VACCINE COMPONENT (75N91019D00024-P00006-759102000027-1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10655272. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*